Get the 5 Tactics in My Longevity Toolkit and my weekly newsletter here (free): bit.ly/3N6vtyL
Watch the full episode: • 281 ‒ Longevity drugs,...
Become a member to receive exclusive content: bit.ly/3O0pEnY
This clip is from 281 Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) with Rich Miller, M.D., Ph.D.
In this clip, Peter and Rich discuss:
- The success of rapamycin as a longevity drug
- Sex-specific differences in longevity drug tests
- Potential issues with drug dose recommendations between men and women
- And more
--------
About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 70 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.
Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan.
Learn more: peterattiamd.com
Connect with Peter on:
Facebook: bit.ly/PeterAtt...
Twitter: bit.ly/PeterAtt...
Instagram: bit.ly/PeterAtt...
Subscribe to The Drive:
Apple Podcast: bit.ly/TheDrive...
Overcast: bit.ly/TheDrive...
Spotify: bit.ly/TheDrive...
Google Podcasts: bit.ly/TheDrive...
Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: peterattiamd.c...
Негізгі бет Rapamycin in mice and other effects outside of longevity | Peter Attia & Rich Miller
Пікірлер: 31